UPDATE ON STROKE IN OLDER PEOPLE: CLINICAL CASES IN EVERYDAY PRACTICE
|
|
- Chastity Evans
- 5 years ago
- Views:
Transcription
1 UPDATE ON STROKE IN OLDER PEOPLE: CLINICAL CASES IN EVERYDAY PRACTICE Joseph SK Kwan Clinical Associate Professor, HKU Honorary Consultant, Queen Mary Hospital & Grantham Hospital
2 CASE: 82 YEAR OLD LADY Sudden R weakness affecting face and leg 1 h ago Dysphasia, hemianopia, NIHSS 15 History of DM, HT, CAD Meds: Amlodipine, Glipizide, Aspirin BP 175/90, P90, afebrile ECG: AF, Bloods: glucose 13 Improved and almost back to normal after 3 h CTB: mild atrophy only, small vessel disease
3 CASE: 82 YEAR OLD LADY What is the diagnosis? What would you do next?
4 CT SIGNS OF EARLY INFARCTION
5 ANATOMY
6 HYPOATTENUATION
7 GREY-WHITE DIFFERENTIATION
8 LENTIFORM NUCLEUS & INSULAR RIBBON
9 SULCAL EFFACEMENT
10 CYTOTOXIC (NOT VASOGENIC) OEDEMA At 4 hours 1 day later
11 HAEMORRHAGIC TRANSFORMATION
12 ENCEPHALOMALACIA, HYDROCEPHALUS EX-VACUO
13 HAEMORRHAGE
14 CASE: 82 YEAR OLD LADY Sudden R weakness affecting face and leg 1 h ago Dysphasia, hemianopia, NIHSS 15 History of DM, HT, CAD Meds: Amlodipine, Glipizide, Aspirin BP 175/90, P90, afebrile ECG: AF, Bloods: glucose 13 Improved and almost back to normal after 3 h MRI: DWI lesion showing new infarct L frontal lobe
15 CASE: 82 YEAR OLD LADY What is the diagnosis? What would you do differently?
16 WHAT IS A TIA? Traditional time-based definition: Focal neurological symptoms of ischemic cause that last <24 hours The old time-based criterion was arbitrarily chosen, based on the belief that brain parenchyma may not be permanently damaged Miller Fisher at the nd Princeton Cerebrovascular Conference
17 MRI IN TIA FLAIR Rovira Am J Neurorad 2002;23:77 a) DWI b) ADC c) MTT d) FLAIR e) GRE f) MRA
18 CASE: 82 YEAR OLD LADY Sudden R weakness affecting face and leg 1 h ago Dysphasia, hemianopia, NIHSS 15 History of DM, HT, CAD Meds: Amlodipine, Glipizide, Aspirin BP 175/90, P90, afebrile ECG: AF, Bloods: glucose 13 Improved and almost back to normal after 3 h MRA: occluded L M1 with fresh clot causing low perfusion, but DWI normal (<3 h)
19 CASE: 82 YEAR OLD LADY What is the diagnosis now? What would you do differently?
20 ACUTE TREATMENT Stroke unit care?severity,?integrated vs. acute unit Immediate Aspirin?dose,?duration,?change to Clopidogrel,??dual vs. single IV rt-pa Europe <3 h all ages, h for <80 yr USA no upper age limit, not FDA approved for >3 h Pan et al. J Stroke Cerebrovasc Dis 2013;22:690
21 RT-PA: NNT TIMING NNT = 2 NNT = 4 NNT = 8 NNT = 14
22 IST-3 Randomised 3035 pts, 53% >80 years Control Rt-PA Rt-PA Control
23 IST-3 Randomised 3035 pts, 53% >80 years Control Rt-PA Rt-PA Control
24 RT-PA BENEFIT FOR >80 YEARS For every 1000 older patients treated <3 h, there are 95 more alive and independent at the end of follow up Symptomatic ICH not higher in older people (OR 1.3 CI )?lower dosage for Asians e.g. 0.9mg/kg max 50mg (Pan et al 2013) Curr Opinion in Neurol 2014;27:8
25 Cerebrovas Dis 2013;36:161
26 REVASCULARISATION Revascularization includes 3 separate concepts: Recanalization = arterial patency Reperfusion = antegrade microvascular perfusion Collateralization = microvascular perfusion via pial arteries or other anastomotic arterial channels that bypass the primary site of vessel occlusion
27 WAKE UP STROKES 1:4 strokes occur in sleep Many wake-up strokes occur close to awakening Neuroimaging approaches may identify wake-up stroke patients likely to benefit from thrombolysis e.g. non-contrast CT, CT-perfusion, penumbral MRI, and diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR). Small case series and observational studies report results of thrombolysis in wake-up stroke, with no safety concerns, but no conclusion on efficacy can drawn. Ongoing clinical trials are enrolling wake-up stroke patients based on neuroimaging findings: DWI-FLAIR-mismatch (WAKE-UP) and penumbral imaging (EXTEND).
28 MISMATCH DWI represents infarct core, PWI identifies the area of critically hypoperfused tissue Lack of cerebral blood flow with decreased intracellular energy metabolism causes cytotoxic edema, which can be detected by a reduced apparent diffusion coefficient (ADC) on DWI within minutes of stroke. During the following 1 4 h, tissue osmolality increases, accompanied by a net increase of water. This absolute increase of water content can be detected by T2-weighted or FLAIR Front Neurol 2014;5:1
29 CASE: 82 YEAR OLD LADY Sudden R weakness affecting face and leg 1 h ago Dysphasia, hemianopia, NIHSS 15 History of DM, HT, CAD Meds: Amlodipine, Glipizide, Aspirin BP 175/90, P90, afebrile ECG: AF, Bloods: glucose 13 Improved and almost back to normal after 3 h MRI: DWI showed 3 new infarcts in L frontal, R occipital, and brainstem
30 CASE: 82 YEAR OLD LADY What is the diagnosis now? What would you do differently?
31 RX TIME WINDOW FOR TIA 1 week Of those who will go on to develop a stroke <3 months, the vast majority will do so within the first week Investigating and treating high risk TIAs can reduce risk of subsequent stroke by 80% (EXPRESS) Lancet Neurol 2009;8:235; BMJ 2004;328:326
32 Stroke risk reductions from randomized trials of antithrombotic agents in atrial fibrillation. Granger C B, and Armaganijan L V Circulation. 2012;125:
33 CHANCE STUDY Randomized, double-blind, multicenter, placebo-controlled trial at 114 centers in China Randomised <24 hours of minor stroke (NIHSS <4) or TIA (ABCD >3) For first 21 days, randomized to a) Group 1 with Clopidogrel (300 mg loading then 75 mg od) + Aspirin ( mg loading dose then 75 mg od), or b) Group 2 with Aspirin alone ( mg loading dose then 75 mg od). Between 21 days and 3 months, patients in Groups 1 and 2 were respectively treated with Clopidogrel (75 mg od) alone or Aspirin (75 mg od) alone. Primary outcome was all stroke at 90 days of follow-up in an intention-to-treat analysis. NEJM 2013;369:11
34 CHANCE STUDY Randomized, double-blind, multicenter, placebo-controlled trial at 114 centers in China Randomised <24 hours of minor stroke (NIHSS <4) or TIA (ABCD >3) For first 21 days, randomized to a) Group 1 with Clopidogrel (300 mg loading then 75 mg od) + Aspirin ( mg loading dose then 75 mg od), or b) Group 2 with Aspirin alone ( mg loading dose then 75 mg od). Between 21 days and 3 months, patients in Groups 1 and 2 were respectively treated with Clopidogrel (75 mg od) alone or Aspirin (75 mg od) alone. Primary outcome was all stroke at 90 days of follow-up in an intention-to-treat analysis. Mean age = 62 (IQR 55-72) NEJM 2013;369:11
35 DAPT Risk of stroke recurrence in dual vs mono APT for patients with AIS or TIA Circulation 2013;128:1656
36 DAPT: MAJOR BLEEDING Circulation 2013;128:1656
37 NOAC Am J Medicine: Anticoagulation in the Post-Warfarin Era: Where Are We Today?
38 NOAC Am J Medicine: Anticoagulation in the Post-Warfarin Era: Where Are We Today?
39
40 NOAC
41 NOAC IN OLDER PEOPLE Frail elderly people not represented in NOAC trials Only <1/3 patients randomized were >75 years old Subgroup analysis = elderly might have a higher risk of extra-cranial bleeding (vs. Warfarin) High risk of renal impairment / deterioration Drug-drug interactions less known Not easily monitored No antidote Dysphagia Use of TCM J Stroke 2014;16:73; Drug Aging 2013;30:949
42 CASE: 82 YEAR OLD LADY 1 month later, admitted w chest pain, raised TNI 0.4, LAD lesion 90% Cardiologist wishes to perform PCI Consults Geri for advice for long term AC BP 160/90, On Warfarin, INR 1.9 What will be your advice?
43 BLEEDING RISK SCORES Comparison of predictive performance of bleeding risk-estimation tools in cohort of patients with AF undergoing PCI in a multicenter European prospective registry. HAS-BLED, ATRIA, mobri, and REACH bleeding risk-prediction scores and assessed the rate of bleeding complications as defined by Bleeding Academic Research Consortium at 12 months follow-up in 929 consecutive patients undergoing PCI. Higher bleeding in a) older patients, b) history of peptic ulcer disease Mean age 74 (11) Am J Cardiol 2014;113:1995
44
45 VKA + APT Study of 8700 patients with mean age 74.2 years Conclusion In AF + stable CAD, addition of APT to VKA has no additional benefit on recurrent coronary events or thromboembolism (incl. stroke), whereas bleeding risk is increased significantly. Circulation 2014;129:1577
46 VKA + APT Study of 8700 patients with mean age 74.2 years Conclusion In AF + stable CAD, addition of APT to VKA has no additional benefit on recurrent coronary events or thromboembolism (incl. stroke), whereas bleeding risk is increased significantly. Older people??12-15% Circulation 2014;129:1577
47 NOAC BETTER FOR ASIANS? RELY = RCT of Dabigatran vs. Warfarin in 2782 patients Stroke rate on W is higher in Asians (3.06%) than non-asians (1.48%) TTR is lower in Asians Hemorrhagic stroke on warfarin occurred more often in Asians than non-asians (HR 2.4; CI ; P=0.007) Reductions in ICH with D may be greater for Asians (D110 vs. W = HR 0.15, D150 vs. W = HR 0.22) than non-asians (D110 vs. W = HR 0.37, D150 vs. W = HR 0.28) Major bleeding rates in Asians were significantly lower on D (both doses) than W (W = 3.82% per year, D110 = 2.22% per year, and D150 = 2.17% per year). Stroke 2013;44:1891
48 CVA ON W = HIGHER, BENEFIT = GREATER Stroke 2013;44:1891
49 BLEED ON W = HIGHER, BENEFIT = GREATER Stroke 2013;44:1891
50 CASE: 82 YEAR OLD LADY Readmitted w acute delirium over 3 days Fell w head injury Hallucination, aggressive Swallow unsafe, no new neurology On Dabigatran + Aspirin BP 170/80 ECG: AF, Bloods/Urine: normal CT: old infarct w new area of infarction and petechial haemorrhage R parietal
51 CASE: 82 YEAR OLD LADY What is the diagnosis? What would you do next?
52 WHEN TO RESTART ANTICOAGULANT Assess competing risks of haematoma growth, recurrent ICH and thromboembolic events Lobar haemorrhage or cerebral amyloid angiopathy = ICH recurrence > thromboembolic risk from AF = stop AC Deep + small ICH + baseline risk of ischemic stroke >6.5% per year (CHADS2 4 or CHA2DS2-VASc 5) = restart AC Time to resumption of AC >10 weeks Thromb Haemost 2014;111:14
53 SEIZURES AFTER STROKE Can be difficult to distinguish post-ictal vs. new stroke vs. both Rt-PA contraindication only if pre-stroke seizure Can present with delirium, LOC, falls Usually responsive to AED First line = Na Valproate, Lamotrigine Second line = Levitiracetam Third line = Gabapentin Avoid Carbamazepine, Phenytoin Zero order pharmacokinetics = PHT, W, A, Alcohol, Theophylline
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationTIA AND STROKE. Topics/Order of the day 1. Topics/Order of the day 2 01/08/2012
Charles Ashton Medical Director TIA AND STROKE Topics/Order of the day 1 What Works? Clinical features of TIA inc the difference between Carotid and Vertebral territories When is a TIA not a TIA TIA management
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with L numbness & slurred speech 2 episodes; 10 mins & 2 hrs Hypertension Type II DM Examination pulse 80/min reg, BP 160/95
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationLa gestione dell ictus ischemico o emorragico nel paziente sotto NAO
La gestione dell ictus ischemico o emorragico nel paziente sotto NAO Antonio Carolei e Cindy Tiseo Clinica Neurologica e Stroke Unit Avezzano - Sulmona Università degli Studi dell Aquila Abano Terme, 10
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationHypertensive Haemorrhagic Stroke. Dr Philip Lam Thuon Mine
Hypertensive Haemorrhagic Stroke Dr Philip Lam Thuon Mine Intracerebral Haemorrhage Primary ICH Spontaneous rupture of small vessels damaged by HBP Basal ganglia, thalamus, pons and cerebellum Amyloid
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with Non-fluent dysphasia R facial weakness Background Ischaemic heart disease Hypertension Hyperlipidemia L MCA branch
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist
ENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist Pharmacy Grand Rounds 26 July 2016 2015 MFMER slide-1 Learning
More informationAcute stroke. Ischaemic stroke. Characteristics. Temporal classification. Clinical features. Interpretation of Emergency Head CT
Ischaemic stroke Characteristics Stroke is the third most common cause of death in the UK, and the leading cause of disability. 80% of strokes are ischaemic Large vessel occlusive atheromatous disease
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationThrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationDr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital
Stroke Management Dr Ben Turner Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital Introduction Stroke is the major cause of disability in the developed
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationRestart or stop antithrombotics after intracerebral haemorrhage (ICH)?
Restart or stop antithrombotics after intracerebral haemorrhage (ICH)? Rustam Al-Shahi Salman professor of clinical neurology & honorary consultant neurologist www.rush.ed.ac.uk @BleedingStroke /bleedingstroke
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationImaging Stroke: Is There a Stroke Equivalent of the ECG? Albert J. Yoo, MD Director of Acute Stroke Intervention Massachusetts General Hospital
Imaging Stroke: Is There a Stroke Equivalent of the ECG? Albert J. Yoo, MD Director of Acute Stroke Intervention Massachusetts General Hospital Disclosures Penumbra, Inc. research grant (significant) for
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationThe DAWN of a New Era for Wake-up Stroke
The DAWN of a New Era for Wake-up Stroke Alan H. Yee, D.O. Stroke and Critical Care Neurology Department of Neurology University of California Davis Medical Center Objectives Review Epidemiology and Natural
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationframework for flow Objectives Acute Stroke Treatment Collaterals in Acute Ischemic Stroke framework & basis for flow
Acute Stroke Treatment Collaterals in Acute Ischemic Stroke Objectives role of collaterals in acute ischemic stroke collateral therapeutic strategies David S Liebeskind, MD Professor of Neurology & Director
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationPatient with high risk for bleeding
Will Apixaban change practice in atrial fibrillation Luncheon Satellite Sponsored by Pfizer Patient with high risk for bleeding Prof. Amos Katz M.D August 2012: patient background 67-year-old woman History
More informationAcute Ischemic Stroke Imaging. Ronald L. Wolf, MD, PhD Associate Professor of Radiology
Acute Ischemic Stroke Imaging Ronald L. Wolf, MD, PhD Associate Professor of Radiology Title of First Slide of Substance An Illustrative Case 2 Disclosures No financial disclosures Off-label uses of some
More informationUnclogging The Pipes. Zahraa Rabeeah MD Chief Resident February 9,2018
Unclogging The Pipes Zahraa Rabeeah MD Chief Resident February 9,2018 Please join Polleverywhere by texting: ZRABEEAH894 to 37607 Disclosures None Objectives Delineate the differences between TPA vs thrombectomy
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationComparison of Five Major Recent Endovascular Treatment Trials
Comparison of Five Major Recent Endovascular Treatment Trials Sample size 500 # sites 70 (100 planned) 316 (500 planned) 196 (833 estimated) 206 (690 planned) 16 10 22 39 4 Treatment contrasts Baseline
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationIMAGING IN ACUTE ISCHEMIC STROKE
IMAGING IN ACUTE ISCHEMIC STROKE Timo Krings MD, PhD, FRCP (C) Professor of Radiology & Surgery Braley Chair of Neuroradiology, Chief and Program Director of Diagnostic and Interventional Neuroradiology;
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationSTROKE - IMAGING. Dr RAJASEKHAR REDDY 2nd Yr P.G. RADIODIAGNOSIS KIMS,Narkatpalli.
STROKE - IMAGING Dr RAJASEKHAR REDDY 2nd Yr P.G. RADIODIAGNOSIS KIMS,Narkatpalli. STROKE Describes a clinical event that consists of sudden onset of neurological symptoms Types Infarction - occlusion of
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationStroke in the ED. Dr. William Whiteley. Scottish Senior Clinical Fellow University of Edinburgh Consultant Neurologist NHS Lothian
Stroke in the ED Dr. William Whiteley Scottish Senior Clinical Fellow University of Edinburgh Consultant Neurologist NHS Lothian 2016 RCP Guideline for Stroke RCP guidelines for acute ischaemic stroke
More informationGiuseppe Micieli Dipartimento di Neurologia d Urgenza IRCCS Fondazione Istituto Neurologico Nazionale C Mondino, Pavia
Giuseppe Micieli Dipartimento di Neurologia d Urgenza IRCCS Fondazione Istituto Neurologico Nazionale C Mondino, Pavia Charidimou et al, 2012 Pathogenesis of spontaneous and anticoagulationassociated
More informationImaging in Stroke. D Nagaraja, N Karthik
Imaging in Stroke D Nagaraja, N Karthik Cerebro-vascular disease (stroke) is the second leading cause of death. Prior to CT era, diagnosis was essentially clinical supported by angio and lumbar puncture.
More informationACUTE STROKE IMAGING
ACUTE STROKE IMAGING Mahesh V. Jayaraman M.D. Director, Inter ventional Neuroradiology Associate Professor Depar tments of Diagnostic Imaging and Neurosurger y Alper t Medical School at Brown University
More informationProtocol for IV rtpa Treatment of Acute Ischemic Stroke
Protocol for IV rtpa Treatment of Acute Ischemic Stroke Acute stroke management is progressing very rapidly. Our team offers several options for acute stroke therapy, including endovascular therapy and
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationShawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists
Shawke A. Soueidan, MD Riverside Neurology & Sleep Specialists 757-221-0110 Epidemiology of stroke 2018 Affects nearly 800,000 people in the US annually Approximately 600000 first-ever strokes and 185000
More informationStroke Update. Claire J. Creutzfeldt, MD January 12, 2018
Stroke Update Claire J. Creutzfeldt, MD January 12, 2018 Disclosures None relevant to this presentation I receive funding from the NINDS What s new in stroke? A new model for cardioembolic stroke: atrial
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDisclosures. An Update on TIA and Minor Stroke. The Agenda PROGNOSIS PATHOPHYSIOLOGY GUIDELINES AND PROVEN MANAGEMENT STRATEGIES AGGRESSIVE TREATMENT
Disclosures An Update on TIA and Minor Stroke Dr. Johnston is principal investigator for the POINT trial, sponsored by the NIH but with drug and placebo contributed by Sanofi-Aventis. S. Claiborne Johnston,
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationIV tpa and mechanical thrombectomy case selection
IV tpa and mechanical thrombectomy case selection 22 April 2017, 9.50-10.30 Deidre De Silva SGH campus, NNI, Singapore OUTLINE Reperfusion concept Case Selection factors IV tpa & Mechanical Thrombectomy
More informationByeong-Keuk Kim, M.D. Ph D. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, M.D. Ph D Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea CASE, M/64 C.C; Recently aggravated chest discomfort for 3 days
More informationAcute Stroke Treatment: Current Trends 2010
Acute Stroke Treatment: Current Trends 2010 Helmi L. Lutsep, MD Oregon Stroke Center Oregon Health & Science University Overview Ischemic Stroke Neuroprotectant trials to watch for IV tpa longer treatment
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationTricky Cases in Primary Care Anticoagulation in AF
Tricky Cases in Primary Care Anticoagulation in AF Dr John Wong GPwSI Cardiology & GP Principal Leatherhead Hospital Ashlea Medical Practice 54 year old F Case 1 PMH CREST Syndrome calcinosis finger tips
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationStroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow
Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia
More informationEndovascular Treatment Updates in Stroke Care
Endovascular Treatment Updates in Stroke Care Autumn Graham, MD April 6-10, 2017 Phoenix, AZ Endovascular Treatment Updates in Stroke Care Autumn Graham, MD Associate Professor of Clinical Emergency Medicine
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationA common clinical dilemma. Ischaemic stroke or TIA with atrial fibrillation MRI scan with blood-sensitive imaging shows cerebral microbleeds
Cerebral microbleeds and intracranial haemorrhage risk in patients with atrial fibrillation after acute ischaemic stroke or transient ischaemic attack: multicentre observational cohort study D. Wilson,
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationWhere are we heading and where are the big challenges?
Where are we heading and where are the big challenges? Christopher Levi Neurologist, John Hunter Hospital, Newcastle & Liverpool Hospital, Sydney Executive Director, Sydney Partnership for Health Education
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationPharmacy STROKE. Anne Kinnear Lead Pharmacist NHS Lothian. Educational Solutions for Workforce Development
STROKE Anne Kinnear Lead Pharmacist NHS Lothian Aim To update pharmacists on Stroke: the disease and its management and explore ways to implement pharmaceutical care for this patient group as part of normal
More information11/1/2018. Disclosure. Imaging in Acute Ischemic Stroke 2018 Neuro Symposium. Is NCCT good enough? Keystone Heart Consultant, Stock Options
Disclosure Imaging in Acute Ischemic Stroke 2018 Neuro Symposium Keystone Heart Consultant, Stock Options Kevin Abrams, M.D. Chief of Radiology Medical Director of Neuroradiology Baptist Hospital, Miami,
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationHow to Interpret CT/CTA for Acute Stroke in the Age of Endovascular Clot Retrieval
How to Interpret CT/CTA for Acute Stroke in the Age of Endovascular Clot Retrieval Peter Howard MD FRCPC Disclosures No conflicts to disclose How to Interpret CT/CTA for Acute Stroke in the Age of Endovascular
More informationPlace for Interventional Radiology in Acute Stroke
Place for Interventional Radiology in Acute Stroke Dr Lakmalie Paranahewa MBBS, MD(Radiology), FRCR Consultant Interventional Radiologist Asiri Group of Hospitals Objectives Imaging in Stroke Neurovascular
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationPaolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia
Anticoagulanti e mono-antiaggregazione: a chi, quali e per quanto tempo Paolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia Anticoagulazione: Bologna,
More informationBoehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017
Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Dr André Peeters Service de Neurologie Cliniques Universitaires Saint-Luc / U.C.L. 1200 BRUXELLES Introduction 1. Aim NOACS
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationISCHEMIC STROKE IMAGING
ISCHEMIC STROKE IMAGING ผศ.พญ พญ.จ ร ร ตน ธรรมโรจน ภาคว ชาร งส ว ทยา คณะแพทยศาสตร มหาว ทยาล ยขอนแก น A case of acute hemiplegia Which side is the abnormality, right or left? Early Right MCA infarction
More informationPeriinterventional management in acute neurointervention
40eme SFNR Congres Paris Periinterventional management in acute neurointervention Peter Berlit Department of Neurology Alfried Krupp Hospital Essen Germany There are 2 evidence based treatment options
More information